Moflaxa (Moxifloxacin)

Moxifloxacin, the active ingredient in Moflaxa, is a fluoroquinolone antibiotic presented as an oral tablet for systemic use. It is indicated for the treatment of bacterial infections such as community‑acquired pneumonia, acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, and skin and soft‑tissue infections in adult patients.

GNH USA supplies Moflaxa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for global healthcare providers.

Moxifloxacin is a fluoroquinolone antibiotic used to treat bacterial infections of the respiratory tract and skin. - Community‑acquired pneumonia: effective treatment to eradicate susceptible pathogens and improve clinical outcomes. - Acute bacterial sinusitis: reduces bacterial load and alleviates sinus inflammation. - Acute bacterial exacerbation of chronic bronchitis: helps resolve infection‑driven worsening of symptoms. - Skin and soft‑tissue infections: combats susceptible Gram‑positive and Gram‑negative organisms in cellulitis and wound infections.

Moxifloxacin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset, usually transient. - Diarrhea: loose stools that are often self‑limiting. - Headache: transient cranial discomfort without neurological signs. - Dizziness: occasional vertigo or light‑headedness, may improve with rest. - Rash: mild skin erythema or pruritus, typically resolves after discontinuation.

Serious or Rare Side Effects: - Tendon rupture: risk of Achilles or other tendon injuries, especially in older adults. - QT prolongation: potential cardiac arrhythmia requiring ECG monitoring in susceptible patients. - Severe allergic reaction: anaphylaxis or angioedema demanding immediate medical attention.

When prescribing Moxifloxacin, clinicians should consider several precautionary measures to ensure safe use. - Assess renal and hepatic function: adjust therapy if impairment is present. - Review patient history for tendon disorders: avoid use in those with recent tendon injury. - Evaluate cardiac risk: caution in patients with known QT prolongation or electrolyte disturbances. - Avoid concomitant use with non‑steroidal anti‑inflammatory drugs (NSAIDs): increased risk of CNS effects. - Monitor for signs of Clostridioides difficile infection: discontinue if severe diarrhea develops. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture.

Moxifloxacin can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Antacids containing aluminum or magnesium: reduce absorption of moxifloxacin. - Warfarin: may enhance anticoagulant effect, increasing bleeding risk. - Cyclosporine: increased serum levels of both agents, risk of toxicity.

Moderate Interactions (Monitor Closely): - NSAIDs: heightened risk of CNS stimulation and seizures. - Theophylline: possible increase in theophylline concentrations. - Corticosteroids: additive risk of tendon rupture.